We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
PURPOSE This phase III trial compared the efficacy and safety of albumin-bound paclitaxel ( nab-paclitaxel ) plus carboplatin with solvent-based paclitaxel ( sb-paclitaxel ) plus carboplatin in advanced non-small-cell lung cancer ( NSCLC ) . PATIENTS AND METHODS In all , 1,052 untreated patients with stage IIIB to IV NSCLC were r and omly assigned 1:1 to receive 100 mg/m(2 ) nab-paclitaxel weekly and carboplatin at area under the concentration-time curve ( AUC ) 6 once every 3 weeks ( nab-PC ) or 200 mg/m(2 ) sb-paclitaxel plus carboplatin AUC 6 once every 3 weeks ( sb-PC ) . The primary end point was objective overall response rate ( ORR ) . RESULTS On the basis of independent assessment , nab-PC demonstrated a significantly higher ORR than sb-PC ( 33 % v 25 % ; response rate ratio , 1.313 ; 95 % CI , 1.082 to 1.593 ; P = .005 ) and in patients with squamous histology ( 41 % v 24 % ; response rate ratio , 1.680 ; 95 % CI , 1.271 to 2.221 ; P < .001 ) . nab-PC was as effective as sb-PC in patients with nonsquamous histology ( ORR , 26 % v 25 % ; P = .808 ) . There was an approximately 10 % improvement in progression-free survival ( median , 6.3 v 5.8 months ; hazard ratio [ HR ] , 0.902 ; 95 % CI , 0.767 to 1.060 ; P = .214 ) and overall survival ( OS ; median , 12.1 v 11.2 months ; HR , 0.922 ; 95 % CI , 0.797 to 1.066 ; P = .271 ) in the nab-PC arm versus the sb-PC arm , respectively . Patients ≥ 70 years old and those enrolled in North America showed a significantly increased OS with nab-PC versus sb-PC . Significantly less grade ≥ 3 neuropathy , neutropenia , arthralgia , and myalgia occurred in the nab-PC arm , and less thrombocytopenia and anemia occurred in the sb-PC arm . CONCLUSION The administration of nab-PC as first-line therapy in patients with advanced NSCLC was efficacious and result ed in a significantly improved ORR versus sb-PC , achieving the primary end point . nab-PC produced less neuropathy than sb-PC
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV